Core B: TCP: Translational Pathology Core

核心 B：TCP：转化病理学核心

• 批准号: 10713055
• 负责人: FRANCESMARY MODUGNO
• 金额: $ 29.18万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10713055
• 关键词: Adipocytes; Area; Ascites; Award; Basic Science; Bioinformatics; Biological Specimen Banks; Biometry; Blood specimen; Bone Marrow; Cancer Center; Cancer Center Support Grant; Cancer Model; Cancer Patient; Cells; Clinic; Clinical; Clinical Data; Collaborations; Communities; Consent; Core Grant; Cryopreservation; Cultured Tumor Cells; Data; Databases; Development; Disease; Endothelial Cells; Ensure; Environment; Fibroblasts; Foundations; Freezing; Funding; Future; Genotype; Goals; Gynecologic; Gynecologic Oncologist; Gynecologic Oncology; Health Insurance Portability and Accountability Act; Human; Immune system; Immunocompromised Host; Individual; Laboratories; Leadership; Learning; Link; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Mesenchymal Stem Cells; Metadata; Modeling; Mus; Myofibroblast; Organoids; Outcome; Paraffin Embedding; Pathologic; Pathologist; Pathology; Patients; Pelvis; Peripheral Blood Mononuclear Cell; Persons; Pre-Clinical Model; Primary Neoplasm; Process; Protocols documentation; Research; Research Institute; Research Personnel; Research Project Grants; Resources; Sampling; Secure; Services; Specimen; Standardization; Suspensions; Testing; Therapeutic; Tissue Sample; Tissues; Training; Translational Research; Treatment outcome; Tumor-Derived; Update; Woman; Work; Xenograft Model; anticancer research; biobank; career; clinical care; data de-identification; data sharing; improved; improved outcome; individual patient; innovation; member; mixed cell culture; neoplastic cell; novel; preclinical study; preservation; programs; repository; research study; stool sample; translational study; tumor; tumor xenograft

PROJECT SUMMARY – TRANSLATIONAL PATHOLOGY CORE The high case-fatality of ovarian cancer makes translational studies essential for advancing treatment and improving outcomes. The Hillman Cancer Center (HCC) Ovarian Cancer (OvCa) SPORE Translational Pathology Core (TPC) will provide four key services to facilitate innovative translational studies: (1) procuring quality-controlled, pathology-reviewed, and clinically-annotated biospecimens, (2) extracting, processing, and storing de-identified clinical data that can be easily integrated with other data types (e.g., genotype, omics, metadata), (3) securely sharing biospecimens and data, and (4) developing patient-derived tumor models for therapeutic and mechanistic studies. The TPC provides these critical services to HCC OvCa SPORE investigators, other NCI-funded OvCa SPOREs, and the greater OvCa research community. A strength of the TPC is the OvCa SPORE Biorepository, established as a part of a previous P50 award to support the translational needs of OvCa researchers. The biorepository enables all persons seen at HCC gynecologic cancer clinics in southwestern PA to donate samples. Consented individuals provide tumor, ascites, pelvic washes, blood, stool, and/or tissue samples for fresh or preserved disbursement. Specimens are longitudinally collected to include samples prior to treatment, throughout the course of clinical care, and at project-specific timepoints. All specimens undergo central pathology review. A novel aspect of the TPC is using primary patient tissues to generate preclinical models to facilitate basic science and preclinical studies. TPC banks single live cell tumor suspensions, isolates and expands primary patient tumor-derived cancer-associated mesenchymal stem cells, and creates mixed cell culture tumor organoids. Primary tumor is also used to generate patient- derived tumor xenografts (PDX) including a new humanized stroma PDX (HS-PDX). HS-PDX can be generated in mice with humanized bone marrow to include a human immune system. TPC will ensure that all samples it collects are accompanied by annotations that will permit linking laboratory analyses with clinical results. Data and annotations will be stored in the OvCa SPORE database and will be updated and retrieved for research projects following established HIPAA protocols. The TPC draws on resources already available through HCC, including the Cancer Center Support Grant (CCSG) cores and the Magee-Womens Research Institute and Foundation (MWRI). As such it efficiently and effectively provides and facilitates the testing of clinically derived data and biospecimens to support OvCa SPORE investigators, and the greater ovarian cancer research community, ultimately improving the lives of patients suffering from this devastating disease.

项目摘要 - 转化病理核心 卵巢癌的高病例肿瘤使转化研究对于推进治疗和 改善结果。希尔曼癌症中心（HCC）卵巢癌（OVCA）孢子翻译 病理核心（TPC）将提供四个关键服务，以促进创新的翻译研究：（1）采购 质量控制，经过病理评审和临床注销的生物测量，（2）提取，加工和 存储可以轻松地与其他数据类型集成的取消识别临床数据（例如基因型，OMICS， 元数据），（3）牢固共享生物测量和数据，以及（4）为患者衍生的肿瘤模型开发用于 治疗和机械研究。 TPC为HCC OVCA孢子提供这些关键服务 调查人员，其他NCI资助的OVCA孢子和更大的OVCA研究社区。强度 TPC是OVCA孢子生物座席，作为先前P50奖的一部分，以支持该奖项 OVCA研究人员的翻译需求。该生物验证能够使所有在HCC妇科中看到的人 西南PA的癌症诊所捐赠样品。同意的人提供肿瘤，腹水，骨盆 洗涤，血液，凳子和/或组织样品，以进行新鲜或保留的支出。标本是纵向的 在治疗前，在整个临床护理过程中以及在特定于项目的过程中收集以包括样品 时间点。所有规格均接受中央病理评论。 TPC的一个新颖方面是使用初级患者 组织生成临床前模型以促进基础科学和临床前研究。 TPC银行单人 细胞肿瘤悬浮液，分离并扩展原发性患者肿瘤衍生的癌症相关的间质 干细胞，并产生混合细胞培养肿瘤器官。原发性肿瘤也用于产生患者 - 衍生的肿瘤特征学（PDX），包括新的人源性基质PDX（HS-PDX）。 HS-PDX可以 在具有人源骨髓的小鼠中产生，包括人类免疫系统。 TPC将确保所有 它收集的样本伴随着注释，这些注释将允许将实验室分析与临床联系起来 结果。数据和注释将存储在OVCA孢子数据库中，并将进行更新和检索 用于建立HIPAA协议之后的研究项目。 TPC利用已经可用的资源 通过HCC，包括癌症中心支持补助金（CCSG）核心和Magee-Womens Research 研究所和基金会（MWRI）。因此，它有效，有效地提供并促进了测试 临床得出的数据和生物测量，以支持OVCA孢子研究者和更大的卵巢 癌症研究界，最终改善了患有这种毁灭性疾病的患者的生活。